Clinical Trial Update: Acute Effect of HP-211 (Axulin) on Blood Glucose and Serum Insulin Responses in Healthy Lean and Overweight Humans [Phase 1]

View source ↗

Summary

Phase 1 trial update assessing acute effects of HP-211 (Axulin) on blood glucose and serum insulin in healthy lean and overweight individuals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Insulin Resistance

Drugs mentioned

• HP-211 (Axulin) (HP-211)

Snippet

Sponsor: Housey Healthcare ULC | Conditions: Insulin Resistance, Diabetes | Phase 1 | Status: COMPLETED | Results posted: 2020-04-20